Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics


Petros Pharmaceuticals Inc. (PTPI): $0.83

-0.07 (-8.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PTPI Stock Price Chart Interactive Chart >

Price chart for PTPI

PTPI Price/Volume Stats

Current price $0.83 52-week high $5.20
Prev. close $0.90 52-week low $0.65
Day low $0.82 Volume 227,569
Day high $0.90 Avg. volume 1,299,449
50-day MA $0.95 Dividend yield N/A
200-day MA $1.71 Market Cap 17.17M

Petros Pharmaceuticals Inc. (PTPI) Company Bio


Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.


PTPI Latest News Stream


Event/Time News Detail
Loading, please wait...

PTPI Latest Social Stream


Loading social stream, please wait...

View Full PTPI Social Stream

Latest PTPI News From Around the Web

Below are the latest news stories about Petros Pharmaceuticals Inc that investors may wish to consider to help them evaluate PTPI as an investment opportunity.

Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement with celebrity physician Dr. Drew Pinsky ("Dr. Drew") to raise awareness, foster dialogue, educate, and alleviate the stigma of erectile dysfunction (ED) and sexual dysfunction within the men's health and wellness landscape. Through this collaboration, Dr. Drew is expected to utilize his medical expertise and social media channels on behal

Yahoo | February 1, 2022

Petros Pharma forms partnership for U.S. production of erectile dysfunction drug Stendra

Petros Pharmaceuticals (PTPI -6.0%) has partnered with a Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the U.S., and is expected to provide both cost savings and increase...

Seeking Alpha | January 24, 2022

Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States

Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces it has partnered with a leading Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the United States, and is expected to provide both cost savings and increase in gross margin.

Yahoo | January 24, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | January 21, 2022

Petros Pharmaceuticals initiates 2 self-selection studies for erectile dysfunction drug

Petros Pharmaceuticals (PTPI) initiated two self-selection studies for its erectile dysfunction ((ED)) drug STENDRA (avanafil).The company said the results of these studies will be part

Seeking Alpha | January 18, 2022

Read More 'PTPI' Stories Here

PTPI Price Returns

1-mo N/A
3-mo -46.79%
6-mo -75.08%
1-year -73.57%
3-year N/A
5-year N/A
YTD -75.08%
2021 -24.32%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4498 seconds.